| Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial AM Borobia, AJ Carcas, M Pérez-Olmeda, L Castaño, MJ Bertran, ... The Lancet 398 (10295), 121-130, 2021 | 436 | 2021 |
| Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance MS Braza, MMT van Leent, M Lameijer, BL Sanchez-Gaytan, RJW Arts, ... Immunity 49 (5), 819-828. e6, 2018 | 212 | 2018 |
| Exploring return dynamics via corridor implied volatility TG Andersen, O Bondarenko, MT Gonzalez-Perez The Review of Financial Studies 28 (10), 2902-2945, 2015 | 129 | 2015 |
| Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals D Lozano-Ojalvo, C Camara, E Lopez-Granados, P Nozal, ... Cell reports 36 (8), 2021 | 103 | 2021 |
| The BCG vaccine for COVID-19: first verdict and future directions M Gonzalez-Perez, R Sanchez-Tarjuelo, B Shor, E Nistal-Villan, ... Frontiers in Immunology 12, 632478, 2021 | 87 | 2021 |
| Model-free volatility indexes in the financial literature: A review MT Gonzalez-Perez International Review of Economics & Finance 40, 141-159, 2015 | 66 | 2015 |
| Reactogenicity and immunogenicity of BNT162b2 in subjects having received a first dose of ChAdOx1s: initial results of a randomised, adaptive, phase 2 trial (CombiVacS) AM Borobia, AJ Carcas, M Pérez Olmeda, L Castaño, M Jesús Bertrán, ... | 34 | 2021 |
| Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR M Schwarz, D Torre, D Lozano-Ojalvo, AT Tan, T Tabaglio, S Mzoughi, ... Nature biotechnology 40 (11), 1680-1689, 2022 | 32 | 2022 |
| Day-of-the-week effect on the VIX. A parsimonious representation MT Gonzalez-Perez, DE Guerrero The North American Journal of Economics and Finance 25, 243-260, 2013 | 30 | 2013 |
| The information content in a volatility index for Spain MT Gonzalez-Perez, A Novales SERIEs 2, 185-216, 2011 | 24 | 2011 |
| Coherent model-free implied volatility: A corridor fix for high-frequency VIX TG Andersen, O Bondarenko, MT Gonzalez-Perez CREATES research papers, 2011 | 20 | 2011 |
| An empirical assessment of proposed solutions for resolving scale problems in value relevance accounting research J Aledo Martinez, JM Garcia Lara, MT Gonzalez Perez, CA Grambovas Accounting & Finance 60 (4), 3905-3933, 2020 | 14 | 2020 |
| Volatility dynamics and the term structure of the variance risk premium N Fusari, MT Gonzalez-Perez Northwestern University, 2012 | 13 | 2012 |
| Uncovering novel features of equity-index return dynamics via corridor implied volatility TG Andersen, O Bondarenko, MT Gonzalez-Perez Available at SSRN 1787528, 2012 | 12 | 2012 |
| CombiVacS Study Group Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled … AM Borobia, AJ Carcas, M Pérez-Olmeda, L Castaño, MJ Bertran, ... Lancet 398 (10295), 121-130, 2021 | 11 | 2021 |
| How Empires Emerge MS Andersen Oslo: NUPI, 2011 | 11* | 2011 |
| A corridor fix for VIX: Developing a coherent model-free option-implied volatility measure TG Andersen, O Bondarenko, MT Gonzalez-Perez 2nd Osaka Conference on “High-Frequency Data Analysis in Financial Markets …, 2011 | 11 | 2011 |
| Development of potent cellular and humoral immune responses in long-term hemodialysis patients after 1273-mRNA SARS-CoV-2 vaccination M Gonzalez-Perez, M Montes-Casado, P Conde, I Cervera, J Baranda, ... Frontiers in Immunology 13, 845882, 2022 | 8 | 2022 |
| Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study J García-Pérez, M González-Pérez, MC de la Osa, AM Borobia, L Castaño, ... EClinicalMedicine 50, 2022 | 5 | 2022 |
| Maintenance of potent cellular and humoral immune responses in long-term hemodialysis patients after 1273-mRNA SARS-CoV-2 vaccination M Gonzalez-Perez, J Baranda, MJ Berges-Buxeda, P Conde, ... Pharmaceuticals 16 (4), 574, 2023 | 4 | 2023 |
